DIBENZYLINE (phenoxybenzamine hydrochloride) by Pfizer is clinical pharmacology phenoxybenzamine hydrochloride is a long-acting, adrenergic, alpha -receptor-blocking agent, which can produce and maintain "chemical sympathectomy" by oral administration. Approved for the treatment of pheochromocytoma, to control episodes of hypertension, sweating and 1 more indications. First approved in 1953.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
Dibenzyline (phenoxybenzamine hydrochloride) is a long-acting alpha-adrenergic receptor blocker approved in 1953 for treating pheochromocytoma and managing hypertensive episodes, sweating, and hypertension. It works by producing 'chemical sympathectomy' through oral administration, increasing blood flow to skin, mucosa, and abdominal viscera while lowering blood pressure. The drug has a 24-hour half-life and cumulative effects over a week of daily dosing.
As a legacy product approaching loss of exclusivity with minimal ongoing Part D utilization data, career opportunities focus on lifecycle management and generic transition planning rather than growth expansion.
CLINICAL PHARMACOLOGY Phenoxybenzamine hydrochloride is a long-acting, adrenergic, alpha -receptor-blocking agent, which can produce and maintain "chemical sympathectomy" by oral administration. It increases blood flow to the skin, mucosa and abdominal viscera, and lowers both supine and erect…
Worked on DIBENZYLINE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Dibenzyline offers limited career growth due to its legacy status and approaching loss of exclusivity; roles focus on managing decline, optimizing niche market share in pheochromocytoma management, and transitioning resources. Pharma professionals on this team gain experience in lifecycle management, generic competition strategy, and specialty market dynamics rather than blockbuster growth trajectories.